Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$36.25 - $43.75 $133,255 - $160,825
-3,676 Reduced 38.07%
5,979 $233,000
Q1 2024

May 14, 2024

BUY
$42.66 - $50.04 $104,772 - $122,898
2,456 Added 34.12%
9,655 $415,000
Q4 2023

Feb 13, 2024

BUY
$28.7 - $46.46 $206,611 - $334,465
7,199 New
7,199 $331,000
Q1 2023

May 11, 2023

SELL
$33.46 - $40.35 $51,227 - $61,775
-1,531 Reduced 13.91%
9,474 $339,000
Q4 2022

Feb 13, 2023

BUY
$33.06 - $39.43 $143,315 - $170,929
4,335 Added 64.99%
11,005 $433,000
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $205,369 - $265,599
6,670 New
6,670 $241,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.42B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.